Andrew Carpenter

Andrew J. Carpenter, Ph.D., is a distinguished leader in the pharmaceutical sciences with a career marked by transformative contributions to drug development, manufacturing innovation, and scientific leadership. He currently serves as the Chief Scientific Officer and Head of Manufacturing, Science & Technology (MS&T) at Phlow Corp. In this capacity, Dr. Carpenter oversees all aspects of Active Pharmaceutical Ingredient (API) development and manufacturing, spearheading scientific research initiatives, and guiding the execution of Research & Development and MS&T projects. He has played an instrumental role in enhancing API production capabilities for both U.S. government and commercial initiatives, emphasizing sustainable, efficient, and high-quality pharmaceutical manufacturing practices.

Dr. Carpenter's expertise in chemistry spans a wide array of critical areas, including continuous processing, process chemistry, and medicinal chemistry. He has a proven track record of leading projects through every phase of drug development and has demonstrated exceptional skill in aligning scientific rigor with business strategy. His work has consistently delivered results, including the successful discovery of new chemical entities, one of which is approaching commercialization—a testament to his dedication and innovation-driven mindset.

Over his career, Dr. Carpenter has held senior leadership roles at prominent organizations such as GlaxoSmithKline, where he led medicinal chemistry programs targeting metabolic diseases and contributed to the identification of multiple clinical candidates. His work there culminated in a peptide program that advanced to human studies, highlighting his collaborative and results-oriented approach. His tenure at Ampac Fine Chemicals and Alcami Corporation further solidified his expertise in managing complex projects that span development to cGMP production, often incorporating cutting-edge technologies such as continuous manufacturing processes.

Dr. Carpenter is also a recognized thought leader in the industry. He has delivered numerous invited talks at prestigious conferences and forums, sharing his insights on pharmaceutical manufacturing, API supply chain innovation, and drug shortage prevention. His scientific contributions are further evidenced by his extensive portfolio of patents, underscoring his commitment to intellectual property protection and novel compound development.

A lifelong learner and passionate scientist, Dr. Carpenter earned his Ph.D. in Organic Chemistry from the University of South Carolina, where he specialized in enantioselective synthesis under the guidance of esteemed mentors. He has received multiple accolades, including the Exceptional Scientist Award from GlaxoSmithKline and numerous fellowships recognizing his excellence in research and teaching.

In addition to his professional accomplishments, Dr. Carpenter is deeply invested in shaping the future of the pharmaceutical industry through thought leadership, collaborative innovation, and more efficient, scalable, and effective drug development processes.